Tracers / [211At]At-211-BC8-B10

[211At]At-211-BC8-B10

Also written as At-211-BC8-B10

Radionuclide: At-211 t½ 431 min
Modality: Therapy
Production route: —
Stage: phase I/II clinical trial
Syntheses indexed: 2

Leukemia (acute and chronic)

What it is

Compound class: Anti-CD45 monoclonal antibody conjugate
Target / mechanism: CD45 PMID 30335787
Clinical application: Allogeneic hematopoietic cell transplantation conditioning for advanced hematopoietic malignancies PMID 30335787
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	custom manifold	SPE	61±16% no	>97%	BC8-B10 (BC8 conjugated with B10-NCS)	30335787 2018 PLoS One 211At-labeling of BC8-B10 was conducted by sequential addition of 1.4 mL of 0.5 M ammonium acetate (pH 5.5) and 1.6 mL of 5 mg/mL BC8-B10 solution (8 mg) to an 211At / 0.05 M NaOH solution — the average percent isolated yield of 211At-BC8-B10 was 61±16%
—	—	—	—	—	—	42224345 2026 Blood

Need this precursor?We can point you to suppliers for [211At]At-211-BC8-B10, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 30335787: 'BC8-B10 (BC8 conjugated with B10-NCS)'. Stage set/updated at stage 23 from PMID 30335787: 'This study has allowed the initiation of a phase I/II clinical trial using 211At-BC8-B10 (NCT03128034).'. | Stage 28: added indication(s) onc-leukemia from consolidated missing-rubric review.